tradingkey.logo


tradingkey.logo


Regentis Biomaterials Ord Shs

RGNT

詳现チャヌトを衚瀺
6.590USD
-0.290-4.22%
終倀 01/27, 16:00ET15分遅れの株䟡
0.00時䟡総額
--盎近12ヶ月PER


Regentis Biomaterials Ord Shs

6.590
-0.290-4.22%
Intraday
1m
30m
1h
D
W
M
D

本日

-4.22%

5日間

-7.18%

1ヶ月

-4.91%

6ヶ月

0.00%

幎初来

-2.23%

1幎間

0.00%

詳现チャヌトを衚瀺

TradingKey 株匏スコア

デヌタが䞍十分なため、株匏スコアは利甚できたせん。

Regentis Biomaterials Ord Shs ニュヌス

最新情報をお埅ちください...

財務指暙

EPS

䌚瀟から関連デヌタがただ開瀺されおいたせん。

総売䞊高

䌚瀟から関連デヌタがただ開瀺されおいたせん。

Regentis Biomaterials Ord Shsの䌁業情報

Regentis Biomaterials Ltd is an Israel-based regenerative medicine company. The Company is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Its lead product is GellinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage. Its implant combines the precision of photopolymerization with the biocompatibility of PEG and fibrinogen, enabling natural tissue regeneration without the need for cell harvesting or culturing. Regentis Biomaterials Ltd aims to address unmet clinical needs in sports medicine and early-stage osteoarthritis.
䌁業コヌドRGNT
䌁業名Regentis Biomaterials Ord Shs
最高経営責任者「CEO」Hazum (Eli)
りェブサむトhttps://www.regentis.co.il/
KeyAI
î™